Q-omics provides the consensus-scored PLPPR4 profile across patient tissues and cancer cell-line models. PLPPR4 expression is associated with patient survival in 21 of 34 cancer types, with the highest sampling consensus in KIRP. Among the 18 cancer types available for tumor–normal comparison, PLPPR4 is differentially expressed in 10, with the highest sampling consensus in HNSC. Additionally, PLPPR4 RNA expression shows 19,272 significant protein co-abundance associations, with the highest sampling consensus in LUAD. Together, these results highlight KIRP, HNSC, and LUAD as cancer lineages where PLPPR4 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for PLPPR4 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes PLPPR4 survival associations across molecular data types. PLPPR4 RNA expression shows survival associations in the most cancer types (21), followed by mutation status (4) and mass-spec protein abundance (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible PLPPR4 RNA expression–survival associations across cancer types. High PLPPR4 expression shows unfavorable associations in KIRP, SCLC, BLCA and UVM, but favorable associations in UCEC and LUAD. The KIRP Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRP as the clearest survival context for PLPPR4 RNA expression.
This table summarizes PLPPR4 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 10. The strongest signals are observed in HNSC for RNA.
This table ranks reproducible tumor–normal expression differences for PLPPR4. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. PLPPR4 shows lower tumor expression in LUSC and BRCA and higher tumor expression in HNSC, COAD, LIHC and KIRC. The HNSC box plot shows higher PLPPR4 RNA expression in tumor versus normal tissue (log2 FC = +0.632, t-test p < 0.001).
This table shows molecular features associated with PLPPR4 in patient tissues and cancer cell lines. In patient samples, PLPPR4 shows the broadest associations at the RNA and protein expression levels, with LUAD recurring as the lineage with the largest associated feature set. In cancer cell lines, PLPPR4 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in URINARY_TRACT, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Lymphoma and BONE.
